DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: esomeprazole sodium

Summary for Generic Name: esomeprazole sodium

Tradenames:2
Patents:2
Applicants:2
NDAs:2
Drug Master File Entries: see list41
Suppliers: see list2
Formulation / Manufacturing:see details

Pharmacology for Ingredient: esomeprazole sodium

Clinical Trials for: esomeprazole sodium

Viokase 16, Viokase16 Plus Nexium and Nexium Alone
Status: Terminated Condition: Chronic Pancreatitis

Nexium Study To Suppress Nausea During Chemotherapy
Status: Terminated Condition: Nausea

A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels
Status: Completed Condition: Arthritis

Prevention of Gastric Ulcers
Status: Completed Condition: NSAID Associated Gastric Ulcers

Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
Status: Completed Condition: Gastroesophageal Reflux Disease

Study Comparing Esomeprazole and Acetylsalicylic Acid (ASA) Combined Together as One Capsule Versus These Medications Taken Separately
Status: Completed Condition: Peptic Ulcer Disease

Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers
Status: Completed Condition: Healthy

The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes
Status: Completed Condition: Type 2 Diabetes

Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination
Status: Completed Condition: Ulcers; Upper GI Symptoms

Ulcer Prevention II
Status: Completed Condition: NSAID Associated Gastric Ulcers

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca
NEXIUM IV
esomeprazole sodium
INJECTABLE;INTRAVENOUS021689Mar 31, 2005RXYes<disabled>
Astrazeneca
NEXIUM IV
esomeprazole sodium
INJECTABLE;INTRAVENOUS021689Mar 31, 2005RXYes5,877,192*PED<disabled>Y
Astrazeneca
NEXIUM IV
esomeprazole sodium
INJECTABLE;INTRAVENOUS021689Mar 31, 2005RXYes6,143,771<disabled>Y
Astrazeneca
NEXIUM IV
esomeprazole sodium
INJECTABLE;INTRAVENOUS021689Mar 31, 2005RXYes6,143,771<disabled>YTHE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc